We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Minimizing Anesthesia in Transcatheter Aortic Valve Implantation: Insights from the DOUBLE-CHOICE Trial

MedXY Editorial Team•Oct 6, 2025•Cardiology
Anesthesiarandomized trialTAVI

Highlight

The DOUBLE-CHOICE trial compared isolated local anesthesia (minimalist approach, MA) with conscious sedation (standard of care, SoC) in transfemoral transcatheter aortic valve implantation (TAVI).

MA was found to be non-inferior to SoC for a composite safety endpoint including mortality, vascular and bleeding complications, infections, and neurologic events at 30 days.

Patients receiving MA reported higher procedural anxiety and stress, suggesting a trade-off between safety/effectiveness and patient comfort.

Study Background and Disease Burden

Aortic stenosis (AS) is a common and life-threatening valvular heart disease in elderly populations, causing significant morbidity and mortality. Transcatheter aortic valve implantation (TAVI) has emerged as an effective, less invasive treatment alternative to surgical valve replacement, especially suited for patients at intermediate or high surgical risk.

With advances in procedural techniques and devices, minimalist strategies for peri-interventional management aimed at reducing invasiveness, procedural time, and resource utilization have gained traction in TAVI practice. Anesthesia and sedation approaches have evolved from general anesthesia to conscious sedation, and more recently to isolated local anesthesia, to enhance patient recovery and reduce complications.

Despite widespread adoption of minimalist anesthesia strategies for TAVI, robust evidence from large randomized controlled trials comparing isolated local anesthesia to conscious sedation was lacking. The DOUBLE-CHOICE trial was designed to fill this evidence gap by investigating the safety and efficacy of these two anesthesia strategies in transfemoral TAVI.

Study Design

This investigator-initiated, open-label, randomized, controlled, 2×2 factorial, multicenter, non-inferiority trial enrolled 752 patients with symptomatic aortic stenosis across 10 German sites between July 2022 and January 2025.

Eligible patients undergoing transfemoral TAVI were randomized to minimalist anesthesia (isolated local anesthesia at the access site) or standard care (conscious sedation). The primary endpoint was a composite of all-cause mortality, vascular and bleeding complications, infections requiring antibiotics, and neurologic events within 30 days post-procedure.

Non-inferiority was assessed in the intention-to-treat population with a prespecified absolute non-inferiority margin of -6% and a one-sided alpha of 0.05.

Key inclusion criteria included symptomatic severe AS; exclusion criteria were not detailed in the summary but typically include contra-indications to TAVI or anesthesia strategies.

Key Findings

A total of 752 patients (377 MA, 375 SoC) were randomized. The median age was 83 years, with 58.5% female participants and a median STS risk score of 4.6%, indicating an intermediate surgical risk cohort.

The primary composite endpoint occurred in 22.9% of the MA group and 25.8% of the SoC group, resulting in a rate difference of 2.9%. The lower boundary of the one-sided 95% confidence interval was -2.4%, meeting the criterion for non-inferiority with a p-value of 0.003. The difference was not statistically significant for superiority (p=0.37), indicating comparable safety profiles between the two anesthesia approaches.

Secondary safety endpoints such as individual components of the primary endpoint (mortality, vascular/bleeding complications, infections, neurologic events) showed no significant differences, supporting the comparable efficacy and safety of MA.

Importantly, patient-reported anxiety and intraprocedural stress levels were higher in the MA group, highlighting potentially greater discomfort with isolated local anesthesia versus conscious sedation. This suggests a trade-off between minimizing anesthesia and patient experience.

No excess adverse events related to localized anesthesia were reported, confirming its feasibility in routine clinical practice.

Expert Commentary

The DOUBLE-CHOICE trial makes a significant contribution by providing randomized evidence supporting the safety of a minimalist anesthesia strategy in TAVI.

This aligns with recent trends favoring streamlined TAVI pathways aimed at reducing procedure complexity, resource consumption, and hospital stay.

However, the increased anxiety and discomfort signals raise important considerations regarding patient selection and peri-procedural support. Management strategies such as anxiolytic premedication or enhanced patient counseling might mitigate these issues.

While the trial was conducted at high-volume German centers with experienced operators, generalizability to lower volume settings and other healthcare systems may require cautious interpretation.

The open-label design and the inability to blind patients or caregivers to anesthesia strategy are intrinsic limitations but unlikely to affect hard clinical endpoints.

Future research should explore tailored anesthesia approaches balancing patient comfort with procedural efficiency and safety and evaluate quality-of-life outcomes, long-term durability of minimalist approaches, and cost-effectiveness analyses.

Conclusion

The DOUBLE-CHOICE trial establishes that isolated local anesthesia is a safe, effective minimalist anesthesia strategy that is non-inferior to conscious sedation for transfemoral TAVI in intermediate-risk elderly patients.

While it offers procedural advantages, clinicians should be mindful of the trade-off with increased patient intraprocedural anxiety and tailor peri-interventional care accordingly.

This evidence supports wider adoption of minimalist anesthesia protocols in well-selected TAVI populations, offering a foundation for protocol standardization and optimization to improve patient outcomes and procedural efficiency.

References

Feistritzer HJ, Ender J, Lauten P, et al. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076557. Epub ahead of print. PMID: 40878766.

Leon MB, Smith CR, Mack M, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010;363(17):1597–1607.

Thiele H, Kurz T, Feistritzer HJ. Minimalistic TAVI in 2020: Where do we stand? EuroIntervention. 2020;16(7):544-547.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Acute Effects of Cannabis Inhalation on Cardiac Ectopy, Physical Activity, Sleep, and Glucose: A Synthesis of Clinical Evidence and Mechanistic InsightsThis review integrates recent randomized trial data with observational studies to clarify cannabis inhalation’s acute impact on cardiac ectopy, physical activity, sleep, and glucose, highlighting complex arrhythmia associations and clAug 15, 2026Levothyroxine in Pregnancy for Subclinical Hypothyroidism or Hypothyroxinemia: No Benefit on Child IQA randomized trial found that levothyroxine treatment for subclinical hypothyroidism or hypothyroxinemia starting between 8 and 20 weeks of gestation did not improve IQ scores in children at age 5 years compared with placebo.Aug 18, 2026WAFER Trial and Beyond: Comparative Efficacy and Pragmatic Implications of WALANT versus General and Regional Anesthesia in Flexor Tendon RepairThis review synthesizes evidence from the WAFER trial and related studies comparing WALANT to GA/RA in flexor tendon repair, highlighting functional outcomes, safety, cost-effectiveness, and patient-centered benefits including earlier returJul 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value
A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.
Jul 3, 2026
Enhancing Preventive Screening Uptake: EHR Portal Messages Boost Mammography RatesIterative redesign of electronic health record (EHR) portal reminders significantly improved mammography screening adherence in an outpatient setting, demonstrating the value of concise messages with scheduling links, while retinal and HbA1Jul 2, 2026
High-Dose Vitamin C After Cardiac Arrest: Promise Meets a Negative Signal in VITaCCAIn a multicenter phase 2 trial, early intravenous vitamin C did not improve post-cardiac arrest organ dysfunction and the 10 g dose was associated with worse outcomes, including renal, cardiac, and neurologic signals.Jun 19, 2026